- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02568267
Korgstudie av Entrectinib (RXDX-101) för behandling av patienter med solida tumörer som innehåller NTRK 1/2/3 (Trk A/B/C), ROS1 eller ALK-genomläggningar (fusioner) (STARTRK-2)
En öppen, multicenter, global fas 2-korgstudie av Entrectinib för behandling av patienter med lokalt avancerade eller metastaserande solida tumörer som har NTRK1/2/3-, ROS1- eller ALK-genomläggningar
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.
Studieöversikt
Status
Betingelser
- Melanom
- Njurcellscancer
- Vuxen fast tumör
- Bröstcancer
- Neoplasmer i huvud och hals
- Kolorektal cancer
- Bukspottskörtelcancer
- Äggstockscancer
- Icke-småcellig lungcancer
- Neuroendokrina tumörer
- Lymfom, storcelligt, anaplastiskt
- Kolangiokarcinom
- Papillär sköldkörtelcancer
- Sarkom
- Spottkörtelcancer
- Primära hjärntumörer
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Utökad åtkomst
Kontakter och platser
Studieorter
-
-
New South Wales
-
Liverpool, New South Wales, Australien, 2170
- Liverpool Hospital
-
Newcastle, New South Wales, Australien, 2305
- Newcastle Private Hospital
-
-
South Australia
-
Bedford Park, South Australia, Australien, 5042
- Flinders Medical Centre
-
-
Victoria
-
Heidelberg, Victoria, Australien, 3084
- Austin Health
-
-
-
-
-
Edegem, Belgien, 2650
- Pharmacy
-
-
-
-
-
Angers, Frankrike, 49055
- Institut de Cancerologie de l Ouest
-
Lyon, Frankrike, 69373
- Centre Leon Berard
-
Marseille, Frankrike, 13915
- Hôpital Nord - AP-HM Marseille#
-
Marseille, Frankrike, 13385
- Hôpital de la Timone
-
Montpellier, Frankrike, 34090
- Institut de Recherche en Cancérologie de Montpellier
-
Toulouse, Frankrike, 31059
- Institut Claudius Regaud
-
Villejuif, Frankrike, 94805
- Institut Gustave Roussy
-
-
-
-
Arizona
-
Phoenix, Arizona, Förenta staterna, 85054
- Mayo Clinic
-
Phoenix, Arizona, Förenta staterna, 85013
- Dignity Health St Joseph's Hospital and Medical Center
-
-
California
-
Duarte, California, Förenta staterna, 91010
- City of Hope Cancer Center
-
Duarte, California, Förenta staterna, 91010
- City of Hope Duarte - Comprehensive Cancer Center, Investigational Drug Services
-
La Jolla, California, Förenta staterna, 92037
- Scripps Clinic
-
La Jolla, California, Förenta staterna, 92093
- University of California San Diego Moores Cancer Center
-
Los Angeles, California, Förenta staterna, 90027
- Southern California Kaiser Permanente
-
Orange, California, Förenta staterna, 92868
- Univ Of California Irvine College Of Medicine
-
San Francisco, California, Förenta staterna, 94158
- UCSF Mission Bay
-
San Francisco, California, Förenta staterna, 94115
- UCSF Mount Zion Medical Ctr
-
Santa Monica, California, Förenta staterna, 90403
- Sarcoma Oncology Center
-
Santa Monica, California, Förenta staterna, 90403
- Sarcoma Oncology Research Center LLC
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80045
- University of Colorado Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Förenta staterna, 6519
- Yale University
-
-
District of Columbia
-
Washington D.C., District of Columbia, Förenta staterna, 20007
- Georgetown University Medical Center Lombardi Cancer Center
-
-
Florida
-
Sarasota, Florida, Förenta staterna, 34232
- Florida Cancer Specialists - Sarasota
-
Tampa, Florida, Förenta staterna, 33612-9497
- Moffitt Cancer Center
-
Tampa, Florida, Förenta staterna, 33612-9497
- H. Lee Moffitt Cancer Center and Research Inst.
-
-
Georgia
-
Athens, Georgia, Förenta staterna, 30607
- University Cancer & Blood Center, LLC
-
Atlanta, Georgia, Förenta staterna, 30322
- Winship Cancer Institute
-
Newnan, Georgia, Förenta staterna, 30265
- Southeastern Regional Medical Center, Inc.
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60611
- Northwestern University
-
Park Ridge, Illinois, Förenta staterna, 60068
- Advocate Medical Group - Park Ridge, Luther Lane - Oncology
-
Zion, Illinois, Förenta staterna, 60099
- Midwestern Regional Medical Center
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21237
- Weinberg Cancer Institution at Franklin Square
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, Förenta staterna, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Förenta staterna, 02215
- Dana Farber Cancer Institute
-
Boston, Massachusetts, Förenta staterna, 02114
- Massachusetts General Hosp CAR
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Förenta staterna, 48201
- Karmanos Cancer Center
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55455
- Regents of the University of Minnesota
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63128
- Washington University
-
-
Nevada
-
Las Vegas, Nevada, Förenta staterna, 89169
- Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley
-
-
New York
-
East Setauket, New York, Förenta staterna, 11733
- North Shore Hem Onc Associates
-
New York, New York, Förenta staterna, 10022
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Charlotte, North Carolina, Förenta staterna, 28204
- Levine Cancer Institute
-
Charlotte, North Carolina, Förenta staterna, 28204
- Atrium Health Levine Cancer Institute
-
Durham, North Carolina, Förenta staterna, 27710
- Duke Cancer Institute
-
-
Ohio
-
Columbus, Ohio, Förenta staterna, 43210
- Ohio State University
-
-
Oklahoma
-
Tulsa, Oklahoma, Förenta staterna, 74133
- Cancer Treatment Centers of America
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97239-3098
- Oregon Health & Science University
-
Portland, Oregon, Förenta staterna, 97239
- Oregon Health & Science Univ
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75230
- Mary Crowley Medical Research Center
-
Temple, Texas, Förenta staterna, 76508
- Baylor Scott & White Health
-
-
Virginia
-
Fairfax, Virginia, Förenta staterna, 22031
- Virginia Cancer Specialists, PC
-
Norfolk, Virginia, Förenta staterna, 23502
- Virginia Oncology Associates - Hampton
-
-
-
-
-
Hong Kong, Hong Kong
- The University of Hong Kong
-
Hong Kong, Hong Kong
- Princess Margaret Hospital
-
Kowloon, Hong Kong
- Queen Elizabeth Hospital
-
Shatin, Hong Kong, 123456
- The Chinese University of Hong Kong
-
-
-
-
Campania
-
Naples, Campania, Italien, 80131
- Seconda Università degli Studi di Napoli
-
-
Lazio
-
Rome, Lazio, Italien, 128
- Università Campus Bio-Medico di Roma
-
-
Lombardy
-
Milan, Lombardy, Italien, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Milan, Lombardy, Italien, 20162
- Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda)
-
-
Tuscany
-
Pisa, Tuscany, Italien, 56126
- Azienda Ospedaliero Universitaria Pisana
-
-
Umbria
-
Perugia, Umbria, Italien, 6132
- Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia
-
-
Veneto
-
Padova, Veneto, Italien, 35128
- IOV - Istituto Oncologico Veneto - IRCCS
-
-
-
-
-
Aichi, Japan, 464-8681
- Aichi Cancer Center Hospital
-
Chūō, Japan, 104-0045
- National Cancer Center Hospital
-
Hyōgo, Japan, 673-8558
- Hyogo Cancer Center, Dept of Respiratory Medicine
-
Matsuyama, Japan, 791-0280
- NHO Shikoku Cancer Center
-
Miyagi, Japan, 981-1293
- Miyagi Cancer Center
-
Niigata, Japan, 951-8566
- Niigata Cancer Center Hospital
-
Osaka, Japan, 589-8511
- Kindai University Hospital
-
Osaka, Japan, 534-0021
- Osaka City General Hospital
-
Shizuoka, Japan, 411-8777
- Shizuoka Cancer Center
-
-
-
-
-
Beijing, Kina, 100142
- Beijing Cancer Hospital
-
Guangzhou, Kina, 528400
- Cancer Center of Guangzhou Medical University
-
Hangzhou, Kina, 310022
- Zhejiang Cancer Hospital
-
Shanghai, Kina, 200120
- Fudan University Shanghai Cancer Center
-
Shanghai, Kina, 200030
- Shanghai chest hospital
-
Shenzhen, Kina, 510852
- Shenzhen People's Hospital
-
-
Heilongjiang
-
Harbin, Heilongjiang, Kina, 150081
- Harbin Medical University Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, Kina, 430023
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- Sichuan Cancer Hospital
-
-
-
-
-
Leiden, Nederländerna, 2333 ZA
- Leids Universitair Medisch Centrum
-
-
-
-
-
Gliwice, Polen, 44-101
- Centrum Onkologii-Instytut im.M.Sklodowskiej Curie
-
Późna, Polen, 60-569
- Szpital Kliniczny Przemienienia Panskiego Uni. Medycznego im. Karola Marcinkowskiego
-
-
-
-
-
Singapore, Singapore, 119228
- National University Hospital
-
Singapore, Singapore, 168583
- National Cancer Centre Singapore
-
-
-
-
-
Barcelona, Spanien, 08035
- Vall d?Hebron Institute of Oncology (VHIO), Barcelona
-
Madrid, Spanien, 28034
- Hospital Universitario Ramon y Cajal
-
Madrid, Spanien, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spanien, 28046
- Hospital Universitario La Paz
-
Madrid, Spanien, 28040
- Hospital Universitario Clínico San Carlos
-
Málaga, Spanien, 29010
- Hospital Clinico Universitario Virgen de la Victoria
-
Seville, Spanien, 41013
- Hospital Universitario Virgen del Rocio
-
-
Madrid
-
Fuenlabrada, Madrid, Spanien, 28942
- Centro Nacional de Investigaciones Oncológicas(CNIO)
-
-
-
-
-
Cambridge, Storbritannien, CB2 0QQ
- Addenbrookes Hospital
-
London, Storbritannien, W1G 6AD
- Sarah Cannon Research Institute
-
Manchester, Storbritannien, M20 4BX
- The Christie
-
-
-
-
-
Seoul, Sydkorea, 03080
- Seoul National University Hospital
-
Seoul, Sydkorea, 06351
- Samsung Medical Center
-
Seoul, Sydkorea, 05505
- Asan Medical Center.
-
Seoul, Sydkorea, 120-752
- Severance Hospital, Yonsei University Health System
-
-
-
-
-
Tainan, Taiwan, 70457
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 11217
- Taipei Veterans General Hospital
-
Taipei, Taiwan, 00100
- National Taiwan University Hospital
-
-
-
-
-
Berlin, Tyskland, 13125
- Evang. Lungenklinik Berlin Klinik für Pneumologie
-
Cologne, Tyskland, 50937
- Universitaetsklinikum Koeln
-
Göttingen, Tyskland, 37075
- Universitaetsmedizin Goettingen
-
Heidelberg, Tyskland, 69120
- NCT Uniklinikum Heidelberg
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement
-
For patients enrolled via local molecular testing, an archival or fresh tumor tissue (unless medically contraindicated) is required to be submitted for independent central molecular testing at Ignyta's CLIA laboratory post-enrollment
-
Measurable or evaluable disease
-
Patients with CNS involvement, including leptomeningeal carcinomatosis, which is either asymptomatic or previously-treated and controlled, are allowed
-
Prior anticancer therapy is allowed (excluding approved or investigational Trk, ROS1, or ALK inhibitors in patients who have tumors that harbor those respective gene rearrangements)
- Note: prior treatment with crizotinib is permitted only in ALK- or ROS1-rearranged NSCLC patients presenting with CNS-only progression. Other ALK inhibitors are prohibited.
-
At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed after prior chemotherapy or small molecule targeted therapy
-
At least 4 weeks must have elapsed since completion of antibody-directed therapy
-
Prior radiotherapy is allowed if more than 14 days have elapsed since the end of treatment
-
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 and minimum life expectancy of 4 weeks
-
Adequate organ function as defined per protocol
-
Ability to swallow entrectinib intact
-
Other protocol specified criteria
Exclusion Criteria:
-
Current participation in another therapeutic clinical trial
-
Prior treatment with approved or investigational Trk, ROS1, or ALK inhibitors in patients who have tumors that harbor those respective gene rearrangements
- Note: prior treatment with crizotinib is permitted only in ALK- or ROS1-rearranged NSCLC patients presenting with CNS-only progression. Other ALK inhibitors are prohibited.
-
History of other previous cancer that would interfere with the determination of safety or efficacy
-
Familial or personal history of congenital bone disorders, or bone metabolism alterations
-
Incomplete recovery from any surgery
-
History of recent (within the past 3 months) symptomatic congestive heart failure or ejection fraction ≤50% observed during screening for the study
-
History of non-pharmacologically induced prolonged QTc interval
-
History of additional risk factors for torsades de pointes
-
Peripheral neuropathy Grade ≥ 2
-
Known active infections
-
Active gastrointestinal disease or other malabsorption syndromes
-
Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis
-
Other protocol specified criteria
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: NTRK1/2/3-rearranged NSCLC
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andra namn:
|
|
Experimentell: ROS1-rearranged NSCLC
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andra namn:
|
|
Experimentell: ALK- or ROS1-rearranged NSCLC
with CNS-only progression previously treated with crizotinib (NOTE: The ALK-rearranged portion of this arm is now closed to enrollment.) Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andra namn:
|
|
Experimentell: NTRK/1/2/3-rearranged mCRC
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andra namn:
|
|
Experimentell: ROS1-rearranged mCRC
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andra namn:
|
|
Experimentell: ALK-rearranged mCRC
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andra namn:
|
|
Experimentell: NTRK1/2/3-rearranged other solid tumor
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andra namn:
|
|
Experimentell: ROS1-rearranged other solid tumor
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andra namn:
|
|
Experimentell: ALK-rearranged other solid tumor
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Objective Response Rate
Tidsram: Approximately 24 months
|
Assessed by blinded independent central review (BICR) using RECIST v1.1 |
Approximately 24 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Duration of Response
Tidsram: Approximately 24 months
|
Assessed by blinded independent central review (BICR) using RECIST v1.1 |
Approximately 24 months
|
|
Time to Response
Tidsram: Approximately 24 months
|
Assessed by blinded independent central review (BICR) using RECIST v1.1 |
Approximately 24 months
|
|
Clinical Benefit Rate
Tidsram: Approximately 24 months
|
Assessed by blinded independent central review (BICR) using RECIST v1.1 |
Approximately 24 months
|
|
Intracranial Tumor Response
Tidsram: Approximately 24 months
|
Assessed by blinded independent central review (BICR) using RANO or RANO-BM, as applicable |
Approximately 24 months
|
|
CNS Progression-free Survival
Tidsram: Approximately 24 months
|
Assessed by blinded independent central review (BICR) using RANO or RANO-BM, as applicable |
Approximately 24 months
|
|
Progression-free Survival
Tidsram: Approximately 30 months
|
Assessed by Kaplan-Meier method |
Approximately 30 months
|
|
Overall Survival
Tidsram: Approximately 36 months
|
Assessed by Kaplan-Meier method |
Approximately 36 months
|
|
Population PK
Tidsram: Approximately 24 months
|
Assessed by Kaplan-Meier method |
Approximately 24 months
|
|
Adverse Events
Tidsram: Approximately 36 months
|
Type, incidence, severity, timing, seriousness, and relatedness of adverse events and laboratory abnormalities, graded by the NCI CTCAE |
Approximately 36 months
|
|
Quality of Life
Tidsram: Approximately 24 months
|
Assessed with the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and the Euro-QoL Group EQ-5D. NSCLC and mCRC patients will complete the lung cancer and colorectal cancer specific modules, QLQ-LC13 and QLQ-CR29, respectively |
Approximately 24 months
|
|
Bone Growth and Bone Mineral Density
Tidsram: Approximately 30 months
|
Assessed with DHA scans |
Approximately 30 months
|
|
Bone Biomarkers
Tidsram: Approximately 30 months
|
Measured by blood |
Approximately 30 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Clinical Trials, Hoffmann-La Roche
Publikationer och användbara länkar
Allmänna publikationer
- Sullivan WG, Hatswell AJ. Letter re: 'Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications'. ESMO Open. 2021 Dec;6(6):100282. doi: 10.1016/j.esmoop.2021.100282. Epub 2021 Oct 28. No abstract available.
- Dziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Farago AF, Lin CC, Karapetis CS, Li YC, Day BM, Chen D, Wilson TR, Barlesi F. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 Apr 10;39(11):1253-1263. doi: 10.1200/JCO.20.03025. Epub 2021 Mar 1.
- Sigal D, Tartar M, Xavier M, Bao F, Foley P, Luo D, Christiansen J, Hornby Z, Maneval EC, Multani P. Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer. J Natl Compr Canc Netw. 2017 Nov;15(11):1317-1322. doi: 10.6004/jnccn.2017.7029.
- Doebele RC, Perez L, Trinh H, Martinec M, Martina R, Riehl T, Krebs MG, Meropol NJ, Wong WB, Crane G. Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC. J Comp Eff Res. 2021 Dec;10(17):1271-1282. doi: 10.2217/cer-2021-0131. Epub 2021 Aug 24.
- Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC; trial investigators. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11.
- Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11.
- Desai AV, Bagchi A, Armstrong AE, van Tilburg CM, Basu EM, Robinson GW, Wang H, Casanova M, Andre N, Campbell-Hewson Q, Wu Y, Cardenas A, Ci B, Ryklansky C, Devlin CE, Meneses-Lorente G, Wulff J, Hutchinson KE, Gajjar A, Fox E. Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. Eur J Cancer. 2025 May 2;220:115308. doi: 10.1016/j.ejca.2025.115308. Epub 2025 Feb 22.
- Choudhury NJ, Jun Woo H, Chen M, Shah R, Donoghue M, Berger M, Drilon A. Serial Cell-Free DNA Sequencing in ROS1 Fusion-Positive Lung Cancers During Treatment With Entrectinib. JCO Precis Oncol. 2024 Jun;8:e2300721. doi: 10.1200/PO.23.00721.
- Yokota T, Yukino H, Doi M, Ohori H. Real-world experience of tropomyosin receptor kinase inhibition with entrectinib in ETV6-NTRK3 positive metastatic salivary secretory carcinoma: A case series. Head Neck. 2023 May;45(5):E10-E15. doi: 10.1002/hed.27346. Epub 2023 Mar 16.
- Ajani JA, D'Amico TA, Bentrem DJ, Corvera CU, Das P, Enzinger PC, Enzler T, Gerdes H, Gibson MK, Grierson P, Gupta G, Hofstetter WL, Ilson DH, Jalal S, Kim S, Kleinberg LR, Klempner S, Lacy J, Lee B, Licciardi F, Lloyd S, Ly QP, Matsukuma K, McNamara M, Merkow RP, Miller AM, Mukherjee S, Mulcahy MF, Perry KA, Pimiento JM, Reddi DM, Reznik S, Roses RE, Strong VE, Su S, Uboha N, Wainberg ZA, Willett CG, Woo Y, Yoon HH, McMillian NR, Stein M. Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 May;23(5):169-191. doi: 10.6004/jnccn.2025.0022.
- Yu Y, Fan Y, Dong X, Li J, Yu Y, Zhao J, Tao S, Chen Y, Chen M, Liu Y, Xu J, Zhu Q, Hu X, Lu S. Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison. Lung Cancer. 2024 Dec;198:108018. doi: 10.1016/j.lungcan.2024.108018. Epub 2024 Nov 10.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Beräknad)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
- Kolorektal cancer
- Icke-småcellig lungcancer
- Bröstcancer
- Äggstockscancer
- Melanom
- Bukspottskörtelcancer
- Kolangiokarcinom
- Neuroendokrina tumörer
- Korgstudie
- Njurcellscancer
- Papillär sköldkörtelcancer
- ROS1
- ALK
- Primära hjärntumörer
- Sarkom
- Entrectinib
- RXDX-101
- TrkA
- TrkB
- TrkC
- NTRK1
- NTRK2
- NTRK3
- Trk Fusions
- NTRK-genomläggningar
- ROS1-fusioner
- ROS1-genomarrangemang
- ALK Fusions
- ALK-genomarrangemang
- Spottkörtelcancer
- Huvud- och halscancer
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Sjukdomar i det endokrina systemet
- Munsjukdomar
- Stomatogena sjukdomar
- Hjärnsjukdomar
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Neoplasmer
- Manliga urogenitala sjukdomar
- Njursjukdomar
- Urologiska sjukdomar
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Tarmsjukdomar
- Immunsystemets sjukdomar
- Luftvägssjukdomar
- Neoplasmer efter histologisk typ
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Gastrointestinala sjukdomar
- Intestinala neoplasmer
- Rektala sjukdomar
- Genitala sjukdomar, kvinnor
- Lungsjukdomar
- Sköldkörtelneoplasmer
- Neoplasmer i endokrina körtel
- Bukspottkörtelsjukdomar
- Neoplasmer, körtel och epitel
- Adenocarcinom
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Kolonsjukdomar
- Lungneoplasmer
- Ovariella sjukdomar
- Adnexala sjukdomar
- Genitala neoplasmer, hona
- Gonadal sjukdomar
- Hudsjukdomar
- Bröstsjukdomar
- Lymfatiska sjukdomar
- Lymfoproliferativa störningar
- Immunproliferativa störningar
- Lymfom, icke-Hodgkin
- Urologiska neoplasmer
- Carcinom
- Neuroektodermala tumörer
- Neoplasmer, könsceller och embryonala
- Neoplasmer, nervvävnad
- Lymfom
- Neoplasmer i nervsystemet
- Neoplasmer i njurarna
- Karcinom, bronkogent
- Bronkiella neoplasmer
- Spottkörtelsjukdomar
- Neoplasmer, bindväv och mjukvävnad
- Nevi och melanom
- Neoplasmer i huden
- Neoplasmer i centrala nervsystemet
- Sköldkörtelsjukdomar
- Adenocarcinom, papillärt
- Neoplasmer i munnen
- Lymfom, T-cell
- Hud- och bindvävssjukdomar
- Hemiska och lymfsjukdomar
- Sköldkörtelcancer, papillär
- Kolorektala neoplasmer
- Ovariella neoplasmer
- Bröstneoplasmer
- Pankreatiska neoplasmer
- Karcinom, njurcell
- Karcinom, icke-småcellig lunga
- Kolangiokarcinom
- Neoplasmer i huvud och hals
- Neuroendokrina tumörer
- Melanom
- Sarkom
- Lymfom, storcelligt, anaplastiskt
- Neoplasmer i hjärnan
- Spottkörtelneoplasmer
- entrecTINIB
Andra studie-ID-nummer
- RXDX-101-02
- 2015-003385-84 (EudraCT-nummer)
- GO40782 (Annan identifierare: Hoffman-La Roche)
- 2023 (U.S.S. NIH-anslag/kontrakt)
- 2015 (U.S.S. NIH-anslag/kontrakt)
- 2023-505034-10-00 (Ctis)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .